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TO THE EDITOR
The aberrant activation of the PI3K/AKT
pathway in melanoma is known to be
caused by genomic deletion, promoter
methylation, or loss-of-function muta-
tions of phosphatase and tensin homo-
log on chromosome 10 (PTEN; see
Madhunapantula and Robertson (2009)
for a review).
More recently, PTEN protein abun-
dance was shown to be decreased at
the posttranscriptional level by a com-
plex microRNA network (He, 2010).
The processed pseudogene of PTEN,
PTENP1, is a modulator of the interac-
tion between PTEN mRNA and PTEN-
targeting microRNAs (Poliseno et al.,
2010). PTENP1 shows extensive se-
quence similarity with PTEN. The high
level of conservation in the most up-
stream region of the 30UTR allows
PTENP1 mRNA to be bound by many
of the microRNA families that bind
PTEN mRNA (Figure 1 and Supplemen-
tal Text S1 online). Therefore, PTENP1
can protect PTEN from microRNA-
mediated downregulation. Consistent
with its activity as a decoy for PTEN-
targeting microRNAs, PTENP1 is a bona
fide tumor suppressor gene that causes
growth inhibition in prostate cancer
cells and undergoes deletion in various
human malignancies (Poliseno et al,
2010).
As recently pointed out (Chen, 2010),
the posttranscriptional regulation of
PTEN levels in melanoma has not been
studied yet and the status of PTENP1 on
9p13 is unknown. Here, we report the
analysis of PTENP1 locus in human
melanoma cell lines and tissues (Sup-
plementary Table S1 online). We also
analyze the relationship between the
following: (1) PTENP1 deletion and
CDKN2A deletion, as they are located
B20cM apart on chromosome 9p
(Bennett, 2008); (2) PTENP1 deletion
and PTEN deletion, as 9p and 10q losses
often coexist in melanoma (Indsto et al.,
1998); (3) PTENP1 deletion and BRAF/
NRAS mutation, as the combination of
mutated BRAF (but not NRAS) and loss
of PTEN expression is a common event
in human melanoma (Tsao et al., 2004).
Our genomic analysis revealed par-
tial deletion of PTENP1 locus in 14.3%
of the cell lines tested (Figure 2a). In
addition, PTENP1 was found to be
deleted in 20.9% of melanoma tissues
(eight partial and one complete dele-
tion; Figure 2b). These results illus-
trate that PTENP1 is under selective
pressure to undergo copy number losses
(Poliseno et al., 2010). The average
PTEN expression level in the 9 samples
with either partial or complete deletion
of PTENP1 (P5, P9, P11, P12, P20, M1,
M9, M14, and M16) was lower
than that in the remaining 34 samples
without any PTENP1 deletion (5.22±
2.30 (N¼ 9) vs. 20.59±3.98 (N¼ 34),
P¼0.06), confirming the protective
effect of PTENP1 on PTEN levels
(Poliseno et al., 2010).
The details of the analyses of
CDKN2A deletion, PTEN deletion, and
BRAF and NRAS mutation in the human
melanoma cell lines and tissues are
provided in Supplemental Text S2 online
(Supplementary Figures S1, S2, and
S3 online).
We observed that the partial or com-
plete deletion of PTENP1 is always
concomitant with the partial or complete
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deletion of CDKN2A in human melano-
ma cell lines, but not in human melano-
ma tissues. The ‘‘focal’’ deletion of
PTENP1 (5/9 cases) has already been
reported in other cancer types, such as
breast and colon cancer (Poliseno et al.,
2010), but is particularly interesting in
melanoma, because it happens in spite of
the fact that CDKN2A deletions are the
most common alterations (Bennett, 2008).
As far as the relationship between
the partial or complete deletion of
PTENP1 and that of PTEN is concerned,
we observed that PTEN is deleted in 7/9
melanoma tissues that show PTENP1
deletion (Figure 2b). This result is
supported by previous loss-of-hetero-
zygosity analyses (Herbst et al., 1999)
and is in agreement with the observa-
tion that 9p and 10q losses often coexist
in melanoma (Indsto et al., 1998).
The codeletion of PTEN and PTENP1
can be reconciled with the function of
PTENP1 as decoy for PTEN-targeting
microRNAs. PTEN deletion, either par-
tial or complete, was found in 23
melanoma tissues. Excluding the cases
in which PTEN deletion is complete,
and therefore PTENP1 deletion cannot
affect PTEN levels, on average we
observed lower PTEN protein expres-
sion in the samples showing both PTEN
partial deletion and PTENP1 deletion
compared with those showing PTEN
partial deletion only, as exemplified by
P5 and M5 tissues in Figure 2b. In
the context of partial PTEN deletion,
PTENP1 deletion may cause a further
decrease in PTEN levels, possibly due
to less efficient sheltering of PTEN-
targeting microRNAs. It is noteworthy
that PTENP1 deletion may also affect
PTEN levels when PTEN is downregu-
lated by mechanisms other than genomic
deletion, such as inactivating mutations.
The biological effects of PTENP1
deletion are likely to be particularly
strong on PTEN because of the intrinsic
nature of this haploinsufficient tumor
suppressor, the variations of which, of
even 20%, can have profound conse-
quences on cancer onset and progres-
sion (Berger and Pandolfi, 2011).
Nevertheless, the concomitant deletion
of PTENP1 and PTEN points toward
PTEN-independent functions of PTENP1
as well. Two possible explanations can
be invoked. First, PTENP1 is likely
to function as decoy for additional
microRNA families that are not PTEN
targeting. These microRNAs should
preferentially bind to the R2 region of
the 30UTR that shows low homology
with the corresponding one on PTEN
(Figure 1a) and might affect targets that
belong to other signaling cascades,
so that the concomitant deletion of
PTENP1 and PTEN causes the activa-
tion of independent pathways that
possibly cooperate in tumorigenesis.
Second, the PTEN-targeting microRNAs
for which PTENP1 functions as decoy
have additional targets. Therefore, the
deletion of PTENP1 might be advanta-
geous for the tumor because of the
decrease of other oncosuppressor genes
besides PTEN (Poliseno et al., 2010).
Examples of these genes are BIM, p21,
and Sprouty2. The proapoptotic factor
BIM is a miR-17 family target (Fontana
et al., 2008). Mutant BRAF and NRAS
induce the MAPK-dependent phosphor-
ylation and consequent proteosomal
PTEN ORF
R1 R2 R3a
ORF
microRNA 
family R1 R2 R3
Conserved in 
PTENP1? Ref.
PTENP1
b
miiR-17
miR-302 yes 1
miR-19 yes (R1) 1–5
miR-21 yes 6
miR-22 yes 1, 7, 8
miR-23 no 9
miR-25 no 1
miR-26 yes (R1) 10
miR-136 yes 11
miR-141 no 12
miR-144 yes 11
miR-193 yes 9
miR-214 yes 13
miR-216 no 14
miR-217 no 14
miR-221 yes 15
miR-486 yes (R1) 16
miR-494 no 17
Figure 1. PTEN- and PTENP1-targeting microRNAs (miRNAs). (a) Schematic representation of PTEN and
PTENP1 30UTR. The most upstream region of the 30UTR (R1, dark gray) is highly conserved between
PTEN and PTENP1. In the middle R2 region (light gray), the conservation drops markedly. The
downstream R3 region (white) is present only in PTEN (modified from Poliseno et al. (2010)). (b) List of
the PTEN-targeting miRNA families validated so far. The region of the 30UTR where the miRNA-binding
sites are located and the conservation of these sites in PTENP1 30UTR are indicated. Out of a total of 18
PTEN-targeting miRNA families, 12 are PTENP1 targeting as well (gray). All these families have at least
one binding site in the high-homology R1 region. Ref., reference; UTR, untranslated region.
Figure 2. Analysis of CDKN2A, CDKN2B, MTAP, PTENP1, PTEN, BRAF, and NRAS status in human melanoma cell lines and tissues. A total of (a) 14 primary
(WM series) and 14 metastatic (Sk-Mel series, 501Mel, A375, and 451Lu) melanoma cell lines and (b) 23 primary (P1–P23) and 20 metastatic (M1–M20)
melanoma tissues were analyzed by quantitative PCR (qPCR) on genomic DNA to identify deletions at 9p21 (CDKN2A, CDKN2B, and MTAP loci), 9p13
(PTENP1 locus), and 10q (PTEN locus). Mutations identified in exons 11 and 15 of BRAF and exons 2 and 3 of NRAS are reported. PTEN protein levels were
analyzed in melanoma tissues by immunohistochemistry (IHC) and the percentage of positive cells is indicated. NA: genomic qPCR was not performed because
of constraints on DNA availability. On the left, IHC shows lower PTEN levels in P5 tissue harboring partial PTEN and PTENP1 deletion compared with M5 tissue
harboring partial PTEN deletion only. Chr., chromosome; Mut, mutated; NA, not available; Wt, wild type. Bars¼ 50mm.
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degradation of BIM in order to provide
melanoma cells with resistance to anoikis
(Akiyama et al., 2009). The CDK inhibitor
p21, another target of the miR-17 family
(Fontana et al., 2008), is repressed
transcriptionally by TBX2 and TBX3
transcription factors, which are frequently
amplified in melanoma and are down-
stream effectors of the MAPK pathway
(Bennett, 2008). Sprouty2 is a wild type
BRAF inhibitor that is targeted by miR-21
(Kwak et al., 2011). The downregulation
of Sprouty2 observed in melanoma has
been hypothesized as an alternative
mechanism responsible for the aberrant
activation of MAPK pathway besides
BRAF mutation (Tsavachidou et al.,
2004). It is noteworthy that the three
genes described above share a common
feature as antagonists of the MAPK path-
way. As the PI3K/AKT and the MAPK
pathways have been shown to cooperate
in melanomagenesis both in vitro and in
mouse models (Dankort et al., 2009;
Meier et al., 2007), it is tempting to
hypothesize that, in the context of PTEN
deletion, the deletion of PTENP1 might
be an alternative mechanism evolved by
the tumor to activate the MAPK pathway.
In this respect, it is worth noticing that
most of the cases showing both PTENP1
and PTEN deletion (71.4%) harbor wild-
type BRAF.
In conclusion, our data indicate that
the recently identified tumor suppressor
gene PTENP1 undergoes genomic dele-
tion in human melanoma. Our data also
suggest that PTENP1 deletion might be
advantageous for the tumor not only
because of its PTEN-related function
but also for PTEN-unrelated ones.
Supplementary material including de-
tailed experimental procedures (Sup-
plemental Text S3 and Supplementary
Tables S2 and S3) is available online.
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TO THE EDITOR
A major goal in cancer prevention is to
identify genetic and environmental risk
factors and determine if they interact to
increase risk. Melanoma is an excellent
model because intermittent sun expo-
sure is a well-supported environmental
risk factor for the development of mela-
noma and a genetic factor, CDKN2A,
has a major role in melanoma etiology.
We have sequenced CDKN2A, the majorAbbreviations: MPM, multiple primary melanoma; SPM, single primary melanoma
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